

# Xiaodong Guan

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3013091/publications.pdf>

Version: 2024-02-01

46  
papers

500  
citations

840776

11  
h-index

888059

17  
g-index

52  
all docs

52  
docs citations

52  
times ranked

365  
citing authors

#	ARTICLE	IF	CITATIONS
1	An analysis of China's national essential medicines policy. <i>Journal of Public Health Policy</i> , 2011, 32, 305-319.	2.0	65
2	The impacts of government reimbursement negotiation on targeted anticancer medication price, volume and spending in China. <i>BMJ Global Health</i> , 2021, 6, e006196.	4.7	29
3	Medical insurance and healthcare utilization among the middle-aged and elderly in China: evidence from the China health and retirement longitudinal study 2011, 2013 and 2015. <i>BMC Health Services Research</i> , 2020, 20, 654.	2.2	25
4	A survey of availability, price and affordability of essential medicines from 2011 to 2016 in Chinese secondary and tertiary hospitals. <i>International Journal for Equity in Health</i> , 2018, 17, 158.	3.5	22
5	Effect of physicians' knowledge on antibiotics rational use in China's county hospitals. <i>Social Science and Medicine</i> , 2019, 224, 149-155.	3.8	22
6	Prices and Clinical Benefit of National Price-Negotiated Anticancer Medicines in China. <i>Pharmacoeconomics</i> , 2022, 40, 715-724.	3.3	21
7	Does the universal medical insurance system reduce catastrophic health expenditure among middle-aged and elderly households in China? A longitudinal analysis. <i>European Journal of Health Economics</i> , 2021, 22, 463-471.	2.8	20
8	Secular trend analysis of antibiotic utilisation in China's hospitals 2011-2018, a retrospective analysis of procurement data. <i>Antimicrobial Resistance and Infection Control</i> , 2020, 9, 53.	4.1	19
9	Influence of government price regulation and deregulation on the price of antineoplastic medications in China: a controlled interrupted time series study. <i>BMJ Open</i> , 2019, 9, e031658.	1.9	17
10	Cost-consequence analysis of salvianolate injection for the treatment of coronary heart disease. <i>Chinese Medicine</i> , 2018, 13, 28.	4.0	15
11	<p></p>Medication Use During Pregnancy in Mainland China: A Cross-Sectional Analysis of a National Health Insurance Database<p></p>. <i>Clinical Epidemiology</i> , 2019, Volume 11, 1057-1065.	3.0	15
12	The impacts of implementation of National Essential Medicines Policies on primary healthcare institutions: a cross-sectional study in China. <i>BMC Health Services Research</i> , 2017, 17, 723.	2.2	14
13	Interrupted time-series analysis of the impact of generic market entry of antineoplastic products in China. <i>BMJ Open</i> , 2018, 8, e022328.	1.9	14
14	How Far Have We Come? Challenges to Orphan Drug Access in China, 2011-2017. <i>Journal of Pharmaceutical Sciences</i> , 2019, 108, 2199-2205.	3.3	14
15	Health Care Utilization and Costs of Patients With Prostate Cancer in China Based on National Health Insurance Database From 2015 to 2017. <i>Frontiers in Pharmacology</i> , 2020, 11, 719.	3.5	14
16	Can locally developed me-too drugs aid price negotiation? An example of cancer therapies from China. <i>Seminars in Oncology</i> , 2021, 48, 141-144.	2.2	14
17	Real-world Use of and Spending on New Oral Targeted Cancer Drugs in the US, 2011-2018. <i>JAMA Internal Medicine</i> , 2021, 181, 1596-1604.	5.1	14
18	Differences in reimbursement listing of anticancer therapies in China: an observational study. <i>BMJ Open</i> , 2020, 10, e031203.	1.9	13

#	ARTICLE	IF	CITATIONS
19	Health technology assessment-informed pricing negotiation in China: higher negotiated price for more effective targeted anticancer medicines?. <i>Health Research Policy and Systems</i> , 2022, 20, 3.	2.8	11
20	Potentially inappropriate medications among elderly patients in community healthcare institutions in Beijing, China. <i>Pharmacoepidemiology and Drug Safety</i> , 2020, 29, 923-930.	1.9	10
21	The impact of physicians' knowledge on outpatient antibiotic use. <i>Medicine (United States)</i> , 2020, 99, e18852.	1.0	10
22	Outpatient Antibiotic Prescribing Patterns and Appropriateness for Children in Primary Healthcare Settings in Beijing City, China, 2017-2019. <i>Antibiotics</i> , 2021, 10, 1248.	3.7	10
23	Safety of medication use during pregnancy in mainland China: based on a national health insurance database in 2015. <i>BMC Pregnancy and Childbirth</i> , 2019, 19, 459.	2.4	9
24	Outpatient prescribing pattern for acute bronchitis in primary healthcare settings in China. <i>Npj Primary Care Respiratory Medicine</i> , 2021, 31, 24.	2.6	8
25	Trends of Negotiated Targeted Anticancer Medicines Use in China: An Interrupted Time Series Analysis. <i>International Journal of Health Policy and Management</i> , 2021, , .	0.9	7
26	Antibiotic use and irrational antibiotic prescriptions in 66 primary healthcare institutions in Beijing City, China, 2015-2018. <i>BMC Health Services Research</i> , 2021, 21, 832.	2.2	7
27	Sales of anti-cancer medicines; China, Indonesia, Kazakhstan, Malaysia, Philippines and Thailand. <i>Bulletin of the World Health Organization</i> , 2020, 98, 467-474.	3.3	7
28	The effect of the implementation of low price medicine policy on medicine price in China: A retrospective study. <i>International Journal of Health Planning and Management</i> , 2018, 33, e798.	1.7	6
29	Review of social networks of professionals in healthcare settings"where are we and what else is needed?. <i>Globalization and Health</i> , 2021, 17, 139.	4.9	6
30	The impact of global budget on expenditure, service volume, and quality of care among patients with pneumonia in a secondary hospital in China: a retrospective study. <i>BMC Public Health</i> , 2020, 20, 522.	2.9	5
31	Anticancer medicines in China: Trends in daily therapy cost and relative procurement volume and spending. <i>Cancer Communications</i> , 2021, 41, 345-348.	9.2	5
32	Communication of Survival Data in US Food and Drug Administration-Approved Labeling of Cancer Drugs. <i>JAMA Internal Medicine</i> , 2021, 181, 1521.	5.1	5
33	Psychotropic medication utilisation in adult cancer patients in China: A cross-sectional study based on national health insurance database. <i>The Lancet Regional Health - Western Pacific</i> , 2020, 5, 100060.	2.9	4
34	Physician patient-sharing relationships and healthcare costs and utilization in China: social network analysis based on health insurance data. <i>Postgraduate Medicine</i> , 2021, 133, 798-806.	2.0	4
35	Clinical Outcome and Medical Cost of Originator and Generic Antihypertensive Drugs: A Population-Based Study in Yinzhou, China. <i>Frontiers in Pharmacology</i> , 2022, 13, 757398.	3.5	3
36	Trends of Fixed-Dose Combination Antibiotic Consumption in Hospitals in China: Analysis of Data from the Center for Antibacterial Surveillance, 2013-2019. <i>Antibiotics</i> , 2022, 11, 957.	3.7	3

#	ARTICLE	IF	CITATIONS
37	Differences of healthcare utilization and cost between cancer inpatients with and without depression: Based on national health insurance database. <i>Psycho-Oncology</i> , 2021, 30, 979-981.	2.3	2
38	Acid Suppression Use Among Infants in One Tertiary Children's Hospital in China, 2015â€“2018: A Retrospective Observational Study. <i>Frontiers in Pediatrics</i> , 2021, 9, 679203.	1.9	2
39	Factors Associated with Free Medicine Use in Patients with Hypertension and Diabetes: A 4-Year Longitudinal Study on Full Coverage Policy for Essential Medicines in Taizhou, China. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 11966.	2.6	2
40	Pharmacogenomics of Leukotriene Modifiers: A Systematic Review and Meta-Analysis. <i>Journal of Personalized Medicine</i> , 2022, 12, 1068.	2.5	2
41	The Impact of Physiciansâ€™ Working Hours on Inappropriate Use of Outpatient Medicine in a Tertiary Hospital in China. <i>Applied Health Economics and Health Policy</i> , 2020, 18, 443-451.	2.1	1
42	Childhood Cancer Drugs in China: An Overview and Comparison of Regulatory Approvals in China and the United States. <i>International Journal of Cancer</i> , 2022, 150, 482-490.	5.1	1
43	Study protocol for the evaluation of pharmacist-participated medication reconciliation at county hospitals in China: a multicentre, open-label, assessor-blinded, non-randomised, controlled study. <i>BMJ Open</i> , 2022, 12, e053741.	1.9	1
44	Misleading Reporting in Statistically Not Significant Oncology Trialsâ€”Joining Efforts Toward Unbiased Results Interpretation. <i>JAMA Network Open</i> , 2021, 4, e2138695.	5.9	1
45	China starts to pay for pharmaceutical services. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2022, 47, 1079-1080.	1.5	1
46	Protocol of a tailored educational intervention for general practitioners on potentially inappropriate medications among older patients at community healthcare institutions in Beijing, China: a cluster-randomised controlled trial. <i>BMJ Open</i> , 2021, 11, e046942.	1.9	0